title: Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.
abstract: A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].
authors.affiliation: U.O.C. Ematologia II con Talassemia, Ospedali Riuniti P.O. Cervello Palermo, Palermo, Italy. aurelio.maggio@ospedaliriunitipalermo.it
authors.forename: Aurelio
authors.initials: A
authors.lastname: Maggio
authors.forename: Angela
authors.initials: A
authors.lastname: Vitrano
authors.forename: Gaetano
authors.initials: G
authors.lastname: Lucania
authors.forename: Marcello
authors.initials: M
authors.lastname: Capra
authors.forename: Liana
authors.initials: L
authors.lastname: Cuccia
authors.forename: Francesco
authors.initials: F
authors.lastname: Gagliardotto
authors.forename: Lorella
authors.initials: L
authors.lastname: Pitrolo
authors.forename: Luciano
authors.initials: L
authors.lastname: Prossomariti
authors.forename: Aldo
authors.initials: A
authors.lastname: Filosa
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Caruso
authors.forename: Calogera
authors.initials: C
authors.lastname: Gerardi
authors.forename: Saveria
authors.initials: S
authors.lastname: Campisi
authors.forename: Paolo
authors.initials: P
authors.lastname: Cianciulli
authors.forename: Michele
authors.initials: M
authors.lastname: Rizzo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: D'Ascola
authors.forename: Angela
authors.initials: A
authors.lastname: Ciancio
authors.forename: Rosario
authors.initials: R
authors.lastname: Di Maggio
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Calvaruso
authors.forename: Gaetano Restivo
authors.initials: GR
authors.lastname: Pantalone
authors.forename: Paolo
authors.initials: P
authors.lastname: Rigano
mesh_terms: D000328:Adult; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology*; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008954:Models, Biological; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D014463:Ultrasonography; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D003676:Deferoxamine